Enanta Pharmaceuticals
ENTA
126 hedge funds and large institutions have $396M invested in Enanta Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 48 reducing their positions, and 32 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 48
2.56% less ownership
Funds ownership: 70.04% → 67.47% (-2.6%)
11% less capital invested
Capital invested by funds: $447M → $396M (-$50.9M)
15% less funds holding
Funds holding: 149 → 126 (-23)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
50% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 32
77% less call options, than puts
Call options by funds: $412K | Put options by funds: $1.79M
Top Buyers
| 1 |
BlackRock
New York
|
+$71.2M |
| 2 |
First Manhattan
New York
|
+$12.3M |
| 3 |
Millennium Management
New York
|
+$10.8M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$9.34M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.26M |
Top Sellers
ENTA Hedge Fund Activity: Q1 2017 in Review
126 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2017, worth a combined $396M — down 11% from $447M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ENTA and 16 opened new positions — a net loss of 16 holders — while 48 trimmed existing stakes and 46 added.
The largest buyer was BlackRock, adding an estimated $71.2M. The largest seller was Great Point Partners, exiting entirely with an estimated $27.7M sold.
- 126 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2017, down from 149 in Q4 2016.
- Funds reported $396M of Enanta Pharmaceuticals stock for Q1 2017, down 11% quarter-over-quarter.
- 16 funds opened new Enanta Pharmaceuticals positions in Q1 2017 and 32 closed out, a net change of -16 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $71.2M added.
- The largest Enanta Pharmaceuticals seller in Q1 2017 was Great Point Partners, an estimated $27.7M sold.
Based on aggregated 13F filings for Q1 2017.